Clinical trial
Study Evaluating Sirolimus in the Treatment of Kidney Transplant
NCT00282217 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00282217 |
|---|---|
| Title | Study Evaluating Sirolimus in the Treatment of Kidney Transplant |
| Official title | Sirolimus in the Treatment of Histological Defined Chronic Allograft Nephropathy |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Kidney Failure, Kidney Diseases |
| Intervention type | Drug |
| Interventions | Sirolimus |
| Enrollment | 100 |
| Start date | Aug 1, 2006 |
| First posted | Jan 25, 2006 |
| Last update posted | Mar 22, 2007 |
| Countries | Spain |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: